Live Breaking News & Updates on சிகிச்சை முதலீட்டாளர் தொடர்பு
Stay updated with breaking news from சிகிச்சை முதலீட்டாளர் தொடர்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α -synuclein levels in vitro and in vivo BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pre-clinical data from its GBA1 Parkinson’s disease program. The findings were highlighted in a presentation at the XXVI International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, a research conference dedicated to Parkinson’s disease and other disorders affecting muscle tone and motor control, being held virtually May 1-4, 2021. ....
Gain Therapeutics Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board. ....
(2) BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. ( Gain ) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board. We are pleased to welcome such a distinguished group of board members at this pivotal time for Gain, said Eric Richman, Chief Executive Officer at Gain. Their decades of experience across the biopharmaceutical industry will be invaluable as we continue to advance our pipeline and determine how our proprietary Site-Directed Enzyme Enhancement Th ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year . Gain TherapeuticsDecember 15, 2020 GMT - Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx) ™ technology for the treatment of rare genetic and neurodegenerative diseases - The collaborative agreement unites resources from the Institute for Research in Biomedicine (IRB)-USI; Neurocentro - Ente Ospedaliero Cantonale (EOC) & GT GAIN Therapeutics, SA LUGANO, Switzerland, Dec. 15, 2020 (GLOBE NEWSWIRE) GT Gain Therapeutics SA (“Gain”), a subsidiary of Gain Therapeutics, Inc., a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, along with the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svi ....
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year Research Collaboration Project with the Institute for Research in Biomedicine and Neurocentro technology for the treatment of rare genetic and neurodegenerative diseases - The collaborative agreement unites resources from the Institute for Research in Biomedicine (IRB)-USI; Neurocentro - Ente Ospedaliero Cantonale (EOC) & GT GAIN Therapeutics, SA LUGANO, Switzerland, Dec. 15, 2020 (GLOBE NEWSWIRE) GT Gain Therapeutics SA ( Gain ), a subsidiary of Gain Therapeutics, Inc., a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, along with the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera Italiana) and the Neurocentro announced today that Innosuisse, the Swiss Innovation Agency, has agreed to support the CHF 1.5M project by funding ....